

**Brovana (arformoterol)
 Perforomist (formoterol)
 Effective 10/01/2021**

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Brovana and formoterol are within the class of sympathomimetics and are long-acting beta agonists approved for treatment of chronic obstructive pulmonary disease.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Brovana or formoterol, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Approval of Brovana and/or formoterol will be granted if the member meets all following criteria and documentation has been submitted:

1. The member has a diagnosis of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema **AND**
2. Clinical rationale why the member is unable to use a non-nebulized long-acting beta-agonist **and has no claims for inhalers within the past 30 days.**

Limitations

1. The following quantity limits apply:

Brovana	#60 vials per 30 days
---------	-----------------------

References

1. Brovana (arformoterol) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2019
2. Perforomist (formoterol) [prescribing information]. Morgantown, WV: Mylan Specialty L.P; May 2019.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: Global Initiative for Chronic Obstructive Lung Disease; 2015.
http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf. Accessed August 7,
4. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. *Chest*. 2008;133(5):1079-1087
5. Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. *COPD*. 2010;7(1):17-31.[\[PubMed 20214460\]](#)

Review History

11/05/07 – Implemented

09/24/07 – Reviewed

09/22/08 – Updated

09/21/09 – Reviewed

09/27/10 – Updated

09/19/11 – Reviewed

09/24/12 – Reviewed

09/23/13 – Reviewed

09/22/14 – Updated

09/21/15 – Reviewed

09/19/16 – Reviewed

09/18/17 – Reviewed

09/18/19 – Added disclaimer on other inhaler use

07/21/2021 – reviewed July P&T; Perferomist came out generic; criteria updated to include formoterol. Started and stabilized statement updated to say “members new to the plan”. Effective 10/01/2021.

